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Background: Extracellular microRNAs enter kidney cells and modify gene expression. We used a Dicer-hepa-
tocyte-specific microRNA conditional-knock-out (Dicer-CKO) mouse to investigate microRNA transfer from
liver to kidney.
Methods: Dicerflox/flox mice were treated with a Cre recombinase-expressing adenovirus (AAV8) to selectively
inhibit hepatocyte microRNA production (Dicer-CKO). Organ microRNA expression was measured in health
and following paracetamol toxicity. The functional consequence of hepatic microRNA transfer was deter-
mined by measuring the expression and activity of cytochrome P450 2E1 (target of the hepatocellular miR-
122), and by measuring the effect of serum extracellular vesicles (ECVs) on proximal tubular cell injury. In
humans with liver injury we measured microRNA expression in urinary ECVs. A murine model of myocardial
infarction was used as a non-hepatic model of microRNA release.
Findings: Dicer-CKO mice demonstrated a decrease in kidney miR-122 in the absence of other microRNA
changes. During hepatotoxicity, miR-122 increased in kidney tubular cells; this was abolished in Dicer-CKO
mice. Depletion of hepatocyte microRNA increased kidney cytochrome P450 2E1 expression and activity.
Serum ECVs from mice with hepatotoxicity increased proximal tubular cell miR-122 and prevented cisplatin
toxicity. miR-122 increased in urinary ECVs during human hepatotoxicity. Transfer of microRNA was not
restricted to liver injury miR-499 was released following cardiac injury and correlated with an increase in
the kidney.
Interpretation: Physiological transfer of functional microRNA to the kidney is increased by liver injury and this
signalling represents a new paradigm for understanding the relationship between liver injury and renal
function.
Funding: Kidney Research UK, Medical Research Scotland, Medical Research Council.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)Keywords:
microRNA
Acute liver injury
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Signalling
ParacetamolV. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
MicroRNAs are key regulators of gene expression [1]. The primary
microRNA transcript is cleaved in the cell nucleus to release a pre-microRNA that is exported into the cytoplasm. The cytoplasmic
enzyme Dicer cleaves the pre-microRNA to produce a microRNA
duplex, one strand of which is loaded onto an Argonaute protein to
form the RNA silencing complex [1]. In the circulation, cell-free
microRNAs are protected from degradation by extra-cellular vesicles
(ECVs) and protein complexes such as Argonaute [2], and they are
potential disease biomarkers [3]. Extra-cellular microRNAs can enter
cells and change gene expression and cellular function in vitro [4].
There is evidence that transfer of microRNA between organs occurs in
Research in context
Evidence before the study
The commonest cause of acute liver injury is paracetamol (acet-
aminophen) overdose. When the liver is injured, renal function
is crucial in determining patient outcome. There is limited
understanding of the pathways that regulate the renal response
to liver injury. Such pathways may represent potential drug tar-
gets. It is established that a microRNA species, miR-122, is
highly expressed specifically in hepatocytes. It is released into
the circulation in high concentration following paracetamol-
induced liver injury in human disease and murine models.
MicroRNAs can enter recipient cells to modulate their RNA tar-
gets. We tested the hypothesis that functional miR-122 is trans-
ferred from the liver to the kidney following liver injury.
Added value of this study
When liver microRNA was depleted in a mouse model there
was a fall in miR-122 (hepatocyte-enriched) in the kidney. Con-
versely, following paracetamol-induced liver injury there was
increased liver-derived miR-122 in kidney tubular cells. Liver-
derived microRNA regulated kidney cytochrome P450 2E1 and
inhibited toxic injury. This signalling pathway is potentially
active in humans  urinary miR-122 was increased with liver
injury.
Implications of all available evidence
miR-122 is released from the injured liver and transferred to
the kidney where it has the potential to modulate the renal
response to injury. This microRNA already represents a drug
target - miravirsen, a locked nucleic acid-modified DNA anti-
sense oligonucleotide which specifically binds miR-122 - has
demonstrated efficacy in a clinical trial to treat hepatitis C.
With development, medicines which target miR-122 may also
be effective treatments to prevent renal failure in patients with
liver disease.
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extra-cellular microRNAs may represent a new class of signalling mol-
ecules and drug targets. In this paper, we tested the hypothesis that
microRNAs produced in the liver are transferred to regulate gene
expression in the kidney. We focussed on the kidney because our ear-
lier work demonstrated that microRNA species can enter kidney tubu-
lar cells under physiological hormonal control and modulate their
mRNA targets [6]. Also, there is a clinically important relationship
between acute liver injury and kidney injury. For example, kidney
function forms an integral part of all the clinical risk stratification mod-
els that are used to make decisions regarding need for liver transplan-
tation to prevent death in patients with acute liver failure [7].
MicroRNA-122 (miR-122-5p, miR-122) is highly expressed in hep-
atocytes (»40,000 copies per cell  around 70% of total hepatocyte
microRNA) [8,9]. In patients with acute liver injury, and in pre-clini-
cal models of liver injury such as paracetamol toxicity, the circulating
concentration of miR-122 is increased 1001000 fold [10]. In over
1000 patients we have demonstrated that miR-122 is a sensitive and
specific biomarker of acute liver injury risk after paracetamol (acet-
aminophen) overdose, the most common cause of acute liver failure
in the Western world [11].
The cytochrome P450 (CYP) enzymes, particularly CYP2E1, are
responsible for generating the toxic metabolite (N-acetyl-p-ben-
zoquinone imine - NAPQI) that causes cell death in the context of
paracetamol toxicity [12]. In the liver, CYP2E1 is established asbeing regulated by miR-122 [13,14]. In the kidney, CYP2E1 is
expressed in tubular cells, a cellular location where it can also
mediate drug toxicity. For example, although rare, paracetamol is
well recognised to directly produce acute kidney injury in the
absence of liver injury [15]. CYP2E1 deletion in mice prevents cis-
platin-induced acute kidney injury demonstrating a central role
for CYP2E1 in this well-established model of nephrotoxicity [16].
In this paper, we explore whether liver to kidney microRNA
transfer regulates kidney CYP2E1 expression and activity, and
whether liver-derived microRNA can modulate nephrotoxic tubu-
lar cell injury.
2. Methods
2.1. Animal Studies
Mice with free access to standard chow and water were housed in
groups of 48 in open-top cages, at 22 °C § 1 °C, 55% humidity and
on a 12 h light dark cycle (lights on at 07:00). The mice were allowed
to acclimatise to the environment for at least a week prior the start of
each experiment. At the end of the study, mice were euthanized
by rising CO2 exposure followed by exsanguination, unless stated
otherwise.
2.1.1. Dicer conditional knock-out (Dicer-CKO)
Dicerflox/flox mice (male and female, 2-3 months old) (B6.Cg-
Dicer1tm1Bdh/J strain) were injected with a single tail vein injection of
the hepatocyte-specific AAV8.TBG.PI.Cre.rBG (AAV8-Cre) or AAV8.
TBG.PI.Null.bGH (AAV8-null) (Penn Vector Core, Pennsylvania, USA,
2.5£ 1011- 6.25£ 1010 viral genomes/100 ml dose in sterile PBS).
Untreated mice Dicerflox/flox (baseline) were used as controls where
indicated. After 14 weeks, blood and tissue were collected. Whole
blood was spun for 10 min at 8000 x g, 4 °C, serum was isolated and
stored at -80 °C. Tissue was placed in 4% paraformaldehyde (Sigma
Aldrich) for 24 h, followed by storage in 70% ethanol and finally par-
affin embedded for sectioning. The rest of the tissue was put into
RNAlater (Sigma Aldrich) and snap frozen for long-term storage at
-80 °C. Prior to tissue collection the circulation was perfused with
sterile saline. Where indicated in the results section, mice were
treated with paracetamol as described below.
2.1.2. Paracetamol hepatotoxicity model
Wild-type male C57BL/6JCrl mice (23 months old) or Dicer-CKO
mice were fasted overnight for 12 h then intraperitoneally injected
with paracetamol (ACROS organics, Geel, Belgium) dissolved in sterile
PBS (Sigma Aldrich, Dorset, UK). Tissue and blood collection occurred
6 hours after paracetamol injection. This time was chosen as it is the
peak time for circulating miR-122 after liver injury. Prior to tissue col-
lection the circulation was perfused with sterile saline. Immediately
following tissue collection, tissue RNA integrity was stabilised and
protected from degradation by collection into RNAlater and immedi-
ate storage at -80 °C. RNA quantity and purity were assessed using
the NanoDrop ND-1000 UV-Vis Spectrophotometer (Thermo Fisher
Scientific) prior to miRNA and mRNA analysis. In specific experi-
ments, circulatory ECVs were isolated from mouse serum as
described previously [17]. In brief, mouse serum was vigorously vor-
texed then centrifuged at 12,500 x g for 30 min. The supernatant was
then centrifuged at 120,000 x g for 70 min to pellet the ECV fraction.
The pellet was washed and then re- centrifuged before final resus-
pension in PBS. In certain studies pelleted ECVs were conjugated
with Cell Tracker 655 (Invitrogen, CA, USA) following the manufac-
turer’s protocol. ECV size distribution and number was measured by
nanoparticle tracking analysis as previously described [18]. Mouse
plasma alanine transaminase activity (ALT) was determined using a
commercial serum ALT kit (Alpha Laboratories Ltd., Eastleigh, UK)
adapted for use on either a Cobas Fara or Cobas Mira analyser
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kidney cells were isolated by fluorescence-activated cell sorting
(FACS). Kidneys were dissociated in RPMI media containing collage-
nase II (Sigma-Aldrich C6885), collagenase D (Roche 11088858001),
dispase (Gibco 17105041) and DNase I (Roche 04716728001). Cells
were then incubated with BD Fc BlockTM purified anti-mouse CD16/
CD32 (BD Biosciences 553141) prior to incubation with fluorescein-
labelled lotus tetragonolobus lectin (LTL, Vector Laboratories FL-1321),
Brilliant Violet 605TM anti-mouse CD31 (Biolegend 102427) and APC
rat anti-mouse CD45 (BD Bioscience 561018). FACS was performed
on the BD FACSAriaTM II apparatus (BD Biosciences).
2.1.3. Coronary artery ligation (CAL) model
CAL was performed in wild-type C57/BL6 mice as described previ-
ously [19,20]. In brief, an incision was made in the lower thorax and
the chest opened at the fourth intercostal space and held open using
retractors. The left anterior descending coronary artery was ligated in
mice randomised to the CAL group, at the level below the left atrium.
After ligation, the chest was closed. For mice undergoing sham sur-
gery, thoracotomy alone was performed; ligation of the left anterior
descending coronary artery was not conducted. An ultra-sensitive
mouse cardiac troponin-I ELISA (Life Diagnostics, Stoke on Trent, UK)
was used on serum as per the manufacturer’s instructions.
2.2. Human studies
Adult patients (age>16 years) admitted to the Royal Infirmary of
Edinburgh, UK following paracetamol overdose without or with acute
liver injury (ALT>1000U/L) were included. Urine was collected and
ECVs were isolated from the whole urine samples as previously
described [18].
2.3. In vitro studies
2.3.1. Primary proximal tubular cell isolation
Male mice were euthanised and kidneys were removed immedi-
ately under aseptic conditions and the cortex macroscopically dis-
sected. The cortex was minced and incubated with 1 mg/ml
collagenase I and IV (Sigma Aldrich, Dorset, UK) for 45 min at 37 °C.
The resultant solution was ground and serially sieved to a final filter
size of 40 mm. The filtered solution was centrifuged at 27,000 x g
through a 48% Percoll gradient (Sigma Aldrich, Dorset, UK) and each
of the 4 distinct bands were carefully removed (F1-4). Cells contained
within the lowermost band (F4) were washed and passed through a
40 mm sieve. The cells were resuspended in DMEM/Hams’s F12
media with glutamax containing: 5 mg/ml insulin, 50 nM hydrocorti-
sone, 10 ng/ml EGF, 5 mg/ml transferrin, 50 nM sodium selenite,
10 nM triiodothyronine, 100 U/ml penicillin, 100mg/ml streptomycin
and 1% (wt/vol) exosome depleted FBS (System Biosciences, CA, US).
Studies of NHE3 and KIM-1 protein expression and alkaline phospha-
tase activity were used to confirm the isolation of proximal tubular
cells (PPT). PPT cells were seeded on at a cell density of
5£ 103 cells/well for 48 hours. Then circulatory ECVs were co-incu-
bated with cells at a concentration of 250£ 108/ml media, 48 h prior
to induction of injury. Nephrotoxic injury was induced by the addi-
tion of cisplatin (Cambridge Bioscience) to PPT cells for 48 h. Experi-
ments were conducted in technical triplicate (3 wells) and biological
quintuplicate (ECVs isolated from 5 animals per group). Cell viability
was determined by the CellTiter-Glo cell viability assay (ATP quanti-
fication) (Promega, Wisconsin, USA) assay and the CellTiter 96
Aqueous Assay (MTS assay) (Promega, Wisconsin, USA) as per manu-
facturer’s instructions.
2.3.2. RNA preparation and qRT-PCR
Total RNA was extracted and purified from serum using the miR-
Neasy Serum/Plasma Kit (Qiagen) with C.elegans miR-39 (Qiagen)added as an external control. Tissue total RNA (250 ng) was extracted
and purified using the miRNeasy Mini Kit (Qiagen). cDNA was syn-
thesised using the miScript II RT kit (Qiagen) according to the manu-
facturer instructions and diluted 1:10 to perform qRT-PCR. MicroRNA
and mRNA quantification was carried out using the miScript SYBR
green PCR kit (Qiagen) on the Lightcycler 480 (Roche Diagnosis).
Quantitect and miScript primers were purchased from Qiagen. For
the quantification of the primary miR-122 transcript, the Taqman
Gene Expression Mix was used for the detection of primary miR-122
transcripts (Life Technologies).
2.3.3. Histological scoring (necrosis quantification)
Liver H&E sections were scored for injury as follows: 100x (dis-
tance (mm) between the central vein and edge of the necrotic zone)/
(total distance (mm) between the central vein and portal triad). 10
measurements chosen at random were made per section.
2.3.4. Immunohistochemistry
CYP2E1 immunohistochemistry in the liver and kidney was per-
formed on the Discovery ULTRA Staining Module (Roche Diagnostics).
For staining preparation, the sections were exposed to 100 °C (4 min)
and incubated with Ventana Cell Conditioner 1 (5£ 8 min). Ventana
DISCOVERY inhibitor (8mins), casesin (1:10,8 min) were then placed
on the slides. With the slides warmed up to 37 °C, the Cytochrome
P450 2E1 antibody (1:100, Abcam, Ab28146) (60mins) and casesin
(1:10, 1£ 8 min) were used. Next, the slides were exposed to anti-
rabbit IgG H (Roche DISCOVERY UltraMap, 7604315) (10mins). To
initiate the signal, the HRP-activated chromagen, DISCOVERY purple
was added (40 min). Finally, Haemotoxylin, followed by bluing
reagent was used as the counterstain.
2.3.5. Western blot
CYP2E1 and Dicer protein expression was quantified by western
blot analysis. Protein homogenate was denatured at 70 °C for 15 min
and each sample was added at 30 mg to either 412% or 420 % tris-
glycine precast gels (NovexTM, WedgewellTM, Invitrogen). Following
1 h of blocking with 5% milk (diluted in TSB-T wash buffer), the pri-
mary antibodies (Supplementary Table 1) were added to 1% milk
(dissolved in TBS-T) and incubated with the membranes (overnight,
4 °C). The membranes were washed with TBS-T (3£ 10 min) and
then transferred into the HRP-secondary antibody (Supplementary
Table 1) (diluted in 1% milk, 1 hour, at room temperature). The mem-
branes were washed as previously described and incubated with
ECL reagent (PierceTM, ThermoFisher Scientific) (5 min, at room tem-
perature). The membranes were exposed to X-Ray film (CL-Xposure
film, ThermoFisher Scientific), developed (Compact 4x, Xograph)
and scanned. After the film development, the membranes were
incubated in acid stripping buffer (2£ 30 min) and washed with
PBS (3£ 3 min) ready to re-probe for b-actin following the methods
above.
2.3.6. In situ hybridisation
miRNA-122 was localised in the liver using the Discovery ULTRA
Staining Module (Roche Diagnostics). During the staining pro-
gramme, the miRCURY LNA miRNA Detection probes (mmu-miR-
122-5p, YD00615338) and controls (U6, YD00699002 and Scramble-
miR, YD00699004) were added. These were prepared using the miR-
CURY LNA miRNA ISH Buffer Set (FFPE) (Qiagen) mixed 1:1 with
UltraPure DEPC water (Thermo Fisher Scientific).
2.3.7. Cytochrome p450 2E1 activity measurements
Tissue was homogenised into a microsomal preparation. The liver
and kidney protein was diluted to 1 mg/ml and 3 mg/ml, respectively
in phosphate buffer (pH 7.4). To determine the CYP2E1 metabolism
activity, the sample was added to the CYP2E1 substrate, chlorzoxa-
zone and NADPH mixture. The reaction was halted by a quench
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10 min after the incubation. Analyte measurements were made on
the Xevo Water TQ-S Mass Spectrometry machine using the Water’s
Masslynx software (Waters Corporation, Massachusetts, United
States). Response of the CYP2E1 enzyme was determined from:
AUC of analyte
AUC of internal control ðVerapamilÞ
2.4. Statistical analysis
All data are presented as median§IQR. When two groups were
compared the Mann-Whitney Test was used. For time course data on
separate mice per time point linear regression was performed then
each treatment was compared to null treatment to determine
whether slopes were significantly different.
2.5. Study approval
All animal studies were performed in accordance with the Ani-
mals (Scientific Procedures) Act 1986 / ASPA Amendment Regulations
2012 following ethical review by the University of Edinburgh. The
local research ethics committee prospectively approved the human
study, and informed consent was obtained from all patients before
entry into the study.
2.6. Role of funders
The funders of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. The
corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
3. Results
3.1. Basal miR-122 in the kidney originates from the liver
To determine whether liver hepatocellular microRNA is trans-
ferred to other organs, we depleted hepatocyte microRNA by treating
Dicerflox/flox mice with a Cre recombinase-expressing adenovirus
(AAV8-Cre) (or control AAV8 which did not express Cre (AAV8-null)).
AAV8 treatment did not result in histological liver injury but mod-
estly increased serum ALT activity. There was no difference between
Cre and null. Liver histology was reviewed by a pathologist blinded
to the treatment grouping (author TJK). Portal-central vascular rela-
tionships were normal. Portal tracts were uninflamed, and there was
no bile duct inflammation, damage or loss. There was no interface
inflammation or ductular reaction. No lobular inflammation, hepato-
cellular injury or loss. No steatosis (Figure S1). Exposure to AAV8-Cre
resulted in a time-dependent decrease in liver Dicer expression at
the mRNA and protein level (Figure S2 and S3). AAV8-null had no
effect on Dicer. Liver depletion of Dicer resulted in a time-dependent
decrease in miR-122, miR-192 and miR-151 (microRNA species
enriched in the liver [21]) (Fig. 1 and S4). There was no significant
microRNA change following AAV8-null injection. To complement our
PCR data and confirm miR-122 depletion, we performed in situ
hybridisation (ISH) on liver tissue, which demonstrated reduced tis-
sue expression with AAV8-Cre treatment (Figure S5). In serum, miR-
122 concentration was reduced when AAV-Cre treated mice were
compared with AAV8-null (normalised to miR-39. Week 3 after AAV8
injection: AAV8-null median 7.4 (IQR 3.354.7); AAV8-Cre 1.3
(0.23.1). Week 4 after AAV8 injection: AAV8-null 4.8 (IQR 0.3-88.1);
AAV8-Cre 0.3 (0.11.5) N=5 per group).
No change in Dicer expression in the kidney (cortex and medulla),
heart or lung occurred, highlighting the liver specificity of Cre deliv-
ery by the AAV8 vector (Figure S2). There was a decrease in brain
Dicer following AAV8-Cre. miR-122 concentration in these non-
hepatic organs was determined alongside selected, organ-enriched,microRNAs (kidney: miR-192, miR-196a; heart: miR-1; lung: miR-
195a; brain: miR-124) [9]. The only microRNA to significantly
decrease following AAV8-Cre treatment of mice was miR-122 in the
kidney cortex and medulla (Fig. 1 and S4). To determine whether
miR-122 was transcribed in the kidney we measured the primary
miR-122 transcript. It was barely detectable in the kidney cortex and
medulla (expression normalised to Gapdh  kidney cortex median
0.0023 (IQR 0.00160.003), in contrast to liver pri-miR-122 1.7
(0.95.4) N=5 per group) and was unaffected by AAV8 treatment (3
weeks after AAV8: null 0.0035 (0.00280.0044). Cre 0.0037
(0.00260.005) N=5 per group). Therefore, the change in miR-122 in
the kidney was not associated with a change in de novo synthesis in
the kidney cells.
3.2. Increased miR-122 transfer to the kidney occurs following liver
injury in mice and humans
We treated wild-type (C57BL/6) mice with a hepatotoxic dose of
paracetamol (300 mg/kg). Published studies demonstrate substan-
tially increased circulating miR-122 6 h after dosing, so this time win-
dow was chosen to study transfer to the kidney [22]. In our study,
after 6 hours, paracetamol resulted in centri-lobular hepatocyte
necrosis and an elevation in serum ALT activity (300 mg/kg dose,
around 38 fold) and serum miR-122 concentration (around 18-fold).
Interestingly, hepatic expression of miR-122 was significantly altered
after paracetamol exposure. There was loss of miR-122 from necrotic
centri-lobular hepatocytes but a marked increase in expression in the
areas surrounding the necrotic cells with the highest expression in
the viable hepatocytes closest to the injured areas (Figure S5). Con-
sistent with hepato-renal transfer, the concentration of miR-122
increased in the kidney cortex and medulla (Fig. 2). To confirm that
the liver was the source of the increase in miR-122 in the kidney we
repeated the experiment with Dicer deletion using the AAV8Cre/Null
(or no AAV8) followed 3 weeks later by paracetamol exposure (0, 150
and 300 mg/kg). In this model paracetamol treatment resulted in his-
tological and biochemical liver injury with higher ALT activity and
increased necrosis in the AAV8-Cre treated group (Figure S6). After
AAV8-Cre treatment, miR-122 expression in the liver tissue following
paracetamol exposure was lost in the areas surrounding necrotic cells
(Figure S5). As in the wild-type mice, there was a significant increase
in kidney cortex and medulla miR-122 in untreated and AAV8-null
treated Dicerflox/flox mice. This increase was substantially attenuated
when the Dicerflox/flox mice were treated with the AAV8-Cre vector
(14-fold difference when AAV8-Cre compared to AAV8-null after
300 mg/kg paracetamol) (Fig. 2). There was no effect on Dicer in the
kidney (Figure S7) and no change in miR-192 or miR-196a (Fig. 2).
There was no expression of the primary miR-122 transcript in the
kidney cortex and medulla without or with paracetamol treatment in
any treatment group (Ct value >35). To determine which kidney cell
type had increased miR-122 after liver injury, we FACS sorted kidney
cells. There was a significant increase only in the miR-122 content of
LTL+ tubular cells (Figure S8).
To begin to translate this pre-clinical work into humans, we mea-
sured miR-122 in urinary ECVs from patients following paracetamol
overdose (without and with acute liver injury, serum ALT activity
>1000U/L  Supplementary Table 2). miR-122 was substantially
increased in the urinary ECVs of those patients with liver injury dem-
onstrating transfer of miR-122 from circulation to the urinary space
in humans with paracetamol hepatotoxicity (Fig. 3). There was no
change in two microRNAs enriched in non-hepatic organs.
3.3. Cardiac microRNA is transferred to the kidney following myocardial
ischaemia
To determine whether microRNA transfer to the kidney is
restricted to liver injury we explored kidney microRNA expression in
Fig. 1. The percentage changes over time in organ microRNA expression after treatment of Dicerflox/flox mice with AAV8 vector expressing or not expressing Cre Recombinase (Cre).
Schematic for study design is presented. In graphs, for each organ, the expression of microRNAs is expressed as a percentage of the untreated Dicerflox/flox mice (baseline). Data are
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normalised to U6. Filled symbols represent mice receiving AAV8-Cre. Unfilled symbols represent AAV8-null. Symbols represent the time point median and the error bars define the
inter-quartile range. N=20 for each AVV8/microRNA combination (N=5 for each time point). Linear regression was performed then for each microRNA Cre treatment was compared
to null treatment to determine whether slopes were significantly different.
Fig. 2. a) miR-122 was increased in the kidney cortex and medulla 6 hours after mice were treated with paracetamol (300mg/kg i.p.). N=10 per group. b) Schematic overview of
study (APAP = paracetamol). C-F) Dicerflox/flox mice were treated with AAV8 vector expressing or not expressing Cre recombinase (Cre or null). 3 weeks after AAV8 treatment mice
received paracetamol 150 or 300 mg/kg (or vehicle (0)) ip, then serum (c), liver (d), kidney cortex (e) and kidney medulla (f) were harvested 6 hours later. Untreated = Dicerflox/flox
mice not receiving AAV8. MicroRNA expression is expressed as U6(ct) - miR (ct). N=5 per group. Statistical significance was determined by Mann-Whitney Test. Data are represented
individual mice with bars representing median and IQR.
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Fig. 3. Urinary extra-cellular vesicles (ECVs) contain miR-122, which was significantly
increased in patients with paracetamol-induced acute liver injury. Urine was collected
from patients who had taken a paracetamol overdose that required treatment but did
not cause liver injury ('No liver injury') and patients with liver injury (ALT>1000U/L).
ECVs were isolated by ultra-centrifugation. MicroRNA concentration was measured
and expression normalised by urinary creatinine. Statistical significance was deter-
mined by Mann-Whitney Test. Data are represented individual patients with bars rep-
resenting median and IQR (N=4-20 per group).
O. Matthews et al. / EBioMedicine 62 (2020) 103092 7a model of ischaemic cardiac injury induced by coronary artery liga-
tion (CAL). Cardiac injury was demonstrated by an increased circulat-
ing troponin concentration 6 hours after CAL (Sham: 1.1 ng/mL (0.9-
1.9). CAL: 22.4ng/mL (17.024.5) P=0.016 N=5 Mann-Whitney Test).
A panel of microRNAs were measured in the circulation and miR-499
was identified as the species with the largest fold increase with CAL
(relative fold increase from baseline 159 (116-813), data not shown
for other species). This increase in the circulation was associated
with a significant decrease in the expression of miR-499 in the left
ventricle of the heart and a concurrent increase in the kidney (Figure
S9). This demonstrates that microRNA released from the heart could
also be transferred to the kidney.3.4. Kidney CYP2E1 and toxic injury is regulated by liver-derived
microRNA
In Dicer flox/flox mice pre-treated with AAV8-Cre, kidney CYP2E1
was significantly increased at the protein and RNA level compared to
AAV8-null in untreated mice and after paracetamol exposure (Fig. 4
a&b, S10). To confirm that enzyme activity is regulated by liver
microRNA we used the chlorzoxazone probe to assay CYP2E1 activity
in liver-derived microsomes. There was a significant increase in liver
CYP2E1 enzyme activity in Dicer flox/flox mice treated with AAV8-Cre
compared to AAV8-null treatment (Fig. 4c).Furthermore, there was
increased CYP2E1 activity in kidney-derived microsomes from AAV8-
Cre treated mice (Fig. 4c). CYP2E1 is the main enzyme responsible for
producing the toxic metabolite of paracetamol. Therefore, we investi-
gated whether there was evidence of renal injury in the AAV8-Cre
treated mice (with lower miR-122 and higher CYP2E1 in the kidney).
There was no histological evidence of injury (data not shown). At the
molecular level, we measured kidney injury molecule 1 (KIM-1)
mRNA expression (an FDA approved biomarker of proximal tubular
injury) [23]. There was no difference in KIM-1 expression when
AAV8 treatment groups were compared (Fig. 4d).Paracetamol does not consistently produce kidney injury in pre-
clinical models or humans following overdose [24]. Therefore, we
developed an ex vivo model to determine whether circulating micro-
RNA released from the injured liver can reduce nephrotoxicity. We
have previously demonstrated that kidney tubular epithelial cells can
take up ECVs and these can deliver functional microRNA into the cells
[6]. In serum from healthy mice we separated ECVs from the non-ECV
fraction. Utilising miR-122 copy number and calculating the average
copies of miR-122 in both fractions quantified the relative distribu-
tion of miR-122. The majority of miR-122 (79.8§6.9%) was located in
the ECV fraction. Therefore, we hypothesised that ECVs transfer miR-
122 from liver to kidney. ECVs were isolated from mouse serum and
their size distribution was characterized by nanoparticle tracking
analysis. The miR-122 concentration of the ECVs from mice with liver
injury due to paracetamol was around 460 and 39 fold higher than
untreated and cardiac injury ECVs, respectively (Fig. 5a). Mouse pri-
mary proximal tubular cells were isolated (Figure S11). Fluores-
cently-labelled ECVs from liver injury mice entered mouse primary
proximal tubular cells (Fig. 5b) and resulted in a significant increase
in proximal tubular cell miR-122 concentration (Fig. 5c). To deter-
mine whether microRNA release from the liver could prevent drug
toxicity in the kidney we cultured mouse primary proximal tubular
cells with equal numbers of ECVs isolated from the following groups:
circulation of untreated mice, mice with liver injury induced by para-
cetamol or mice with cardiac injury induced by CAL. ECV treatment
for 48 h was followed by exposure of the cells to cisplatin (the toxic-
ity of which is dependent on CYP2E1 activity [16]) at the EC50 toxic-
ity dose (Fig. 5d). The ECVs from mice with liver injury significantly
attenuated cisplatin toxicity. By contrast, ECVs from healthy mice
and mice with cardiac injury had no effect (Fig. 5e&f).
4. Discussion
The work described in this paper demonstrates that miR-122 is
transferred from the liver to the kidney tubular cells as a physiologi-
cal process (in the uninjured mouse) that is increased by acute liver
injury. In the kidney, microRNA originating from the liver regulated
CYP2E1 RNA and protein expression and activity and attenuated cis-
platin toxicity. In humans with paracetamol toxicity there is evidence
of increased miR-122 in urinary ECVs, which supports our mouse
data being a faithful reflection of human pathophysiology. miR-122
has two unique properties which facilitated our experiments. Firstly,
it is highly enriched in hepatocytes compared to other organs. Data
from the FANTOM consortium demonstrates that miR-122 is approxi-
mately 18,000 higher in hepatocytes than renal proximal tubular
cells [9]. Secondly, it is released in large amounts from the injured
liver into the circulation. These properties allowed us to use miR-122
to track endogenous microRNA transfer by liver-specific deletion of
the enzyme that generates mature microRNA species (Dicer). This
approach also allowed us to confidently exclude off-target Cre recom-
binase activity in non-hepatic organs by measurement of Dicer and
organ-selective microRNAs. When Dicer was deleted in the liver
there was a subsequent substantial miR-122 decrease in the kidney.
The primary transcript for miR-122 was undetectable in the kidney.
The FANTOM consortium used RNA-sequencing and cap analysis of
gene expression (CAGE) across multiple primary cell types. This dem-
onstrated the presence of mature miR-122 in kidney proximal tubu-
lar cells without expression of its promoter [9]. This supports the
conclusion from our studies - miR-122 expression in the kidney
results from transfer from the liver. This is consistent with the results
of Rivkin et al.who used macrophage depletion or antagomirs to indi-
rectly inhibit LPS-induced miR-122 release from mouse hepatocytes
and reported a corresponding reduction of kidney miR-122 [25]. The
data presented in our paper now demonstrate that microRNA trans-
fer from the liver to the kidney occurs as part of normal physiology
and does not require experimental induction of inflammation or
Fig. 4. Dicerflox/flox mice were treated with AAV8 vector expressing or not expressing Cre recombinase (Cre or null). a) Western blot of kidney cortex CYP2E1 A, C, E. mice treated
with AAV8 null then kidney collected 1, 2 or 3 weeks later. B, D, F mice treated with AAV8 Cre then kidney collected 1, 2 or 3 weeks later b) Cytochrome P450 2E1 (CYP2E1) mRNA
expression is expressed as b-actin(ct) - CYP2E1 (ct). 3 weeks after AAV8 treatment mice received paracetamol 150 or 300 mg/kg (or vehicle (0)) ip, then the kidney cortex was har-
vested 6 hours later. c). CYP2E1 activity was determined by metabolism of chlorzoxazone.d) Kidney injury molecule 1 (KIM-1) mRNA expression in the kidney cortex following
paracetamol (300mg/kg ip) in no AAV8 treated (untreated), AAV8 null and AAV8 Cre treated mice. KIM-1 is normalized by beta-actin. For a-d, statistical significance was determined
by Mann-Whitney Test. Data are represented individual mice with bars representing median and IQR (N=5 per group).
8 O. Matthews et al. / EBioMedicine 62 (2020) 103092tissue injury. It is likely that multiple microRNA species are trans-
ferred from liver to kidney as part of normal physiology. The unique
properties of miR-122 described above allow us to detect a change
whereas other microRNAs will be synthesised locally in the kidney.
This local expression is likely to mask any change due to decreased
transfer from the liver (a hypothesis supported by miR-192 not
changing in the kidney despite a decrease in the liver). Future studies
should define the total contribution of liver-derived RNA in the kid-
ney.
Circulating microRNAs change with tissue injury as exemplified
by the increase in miR-122 that accompanies liver injury. In this
paper we demonstrate that miR-122 released as a result of paraceta-
mol toxicity targets the kidney tubular cells. miR-122 did not increase
in the kidney of the null mice (without paracetamol treatment)
despite some of the mice having an increase in ALT activity (supple-
mentary figure 1). We speculate that this reflects miR-122 circulating
concentrations being lower after AAV8 exposure than following para-
cetamol (3 weeks after AAV8 null median (IQR) 3523 (105637,548);
4 weeks 2086 (7953,734); post-paracetamol 300 mg/kg 96406
(27,949224,426) copies per mL). There may be a threshold concen-
tration of miR-122 in the circulation that needs to be reached beforethere is an increase in the kidney. Fig. 2 in our paper also supports
this possibility. In Fig. 2c there was a small increase in miR-122 in the
serum of null mice treated with the 150 mg/kg dose of paracetamol
which did not result in an increase in the kidney (Fig. 2e and f). Trans-
fer to the kidney was also demonstrated using a model of ischemic
injury to the myocardium with miR-499 as the target microRNA. This
demonstrates that the kidney is a key node that internalises micro-
RNA released from injured organs. Recent in vivo data demonstrate
that miR-122 released from the injured liver can induce acute lung
inflammation by activating alveolar macrophages [26]. In our studies
there was not a significant decrease in lung miR-122 following liver
microRNA depletion. In contrast to the kidney, this suggests that
microRNA transfer from the liver to the lung is not significant in the
healthy uninjured state. In humans, the cargo of miR-122 in urinary
ECVs is substantially increased when the liver is injured which sup-
ports our mouse model of liver to kidney transfer occurring in human
disease. The mechanism by which miR-122 goes from the circulation
to urinary ECVs remains to be defined. It could be that ECVs transfer
from blood to urine. Alternatively, miR-122 containing ECVs could be
generated de novo by the kidney tubular cells when the liver is
injured. However, our mouse model clearly demonstrates that the
Fig. 5. a) miR-122 in ECVs from serum of healthy mice, mice with liver injury (300mg/kg paracetamol IP) or cardiac injury (induced by CAL). b). Murine primary proximal tubular
(PTT) cells internalize ECVs (red). Green represents KIM-1, an archetypal proximal tubular protein. Blue stain is DAPI. c) ECVs were isolated from the serum of mice treated with a
toxic dose of paracetamol (300mg/kg ip - liver injury ECV) or healthy mice. Equal ECV numbers were applied to PTT cells and the miR-122 content of the cells was determined. d)
PPT cells were exposed to cisplatin for 48 hours prior to assessment of cell viability by NADPH activity (N=4). e & f). PTT cells were co-incubated with circulatory ECVs (250£ 108/
ml) for 48 hours and subsequently injured with 10 mM cisplatin. Circulatory ECVs were derived from healthy mice (control), liver injury mice (300mg/kg paracetamol IP) or cardiac
injury induced by CAL. Cells that were not injured with cisplatin and had no additional ECVs added are labeled no injury. All results were normalised to the results from PTT cells
injured with 10 mM cisplatin with no additional ECVs (baseline). Data represents ATP concentration (Figure e) and NADPH activity (Figure f) as percentage change from baseline.
Statistical significance was determined by Mann-Whitney Test. Data are represented individual mice with bars representing median and IQR (N=5 per group). *=P=0.008 compared
to baseline.
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liver. Therefore, we postulate that the increase in urinary ECV miR-
122 supports the existence of liver to kidney transfer in humans.
There are many different pathways that could be regulated in the
kidney by microRNA originating from other organs and this will be a
subject of further research. We focussed on CYP2E1 because it is
established as being regulated by miR-122 and it is a key enzyme in
the drug metabolism that underlies liver and kidney toxicity. Our
data demonstrate that CYP2E1 RNA and protein expression and enzy-
matic activity is regulated by liver-derived microRNA in the liver and
the kidney. As others have reported, the consequence of microRNA
depletion in the liver was increased injury following paracetamol
exposure [13,14]. Interestingly, in the liver, miR-122 was substan-
tially increased in the hepatocytes surrounding the necrotic core
(miR-122 expression was lost from the core). This effect was not
apparent when bulk tissue expression was measured by PCR. Theo-
retically, transfer of miR-122 may reduce drug toxicity in the kidney
by down-regulating CYP enzyme activity. Paracetamol is not a robust
model for acute kidney injury with multiple studies demonstrating
little or no injury occurs despite significant liver injury [24]. Future in
vivo studies could explore the effect of hepatic microRNA depletion
on the renal response in established rodent kidney injury models
such as ischaemia/reperfusion, cisplatin nephrotoxicity or sepsis
models. To start this process of exploring the potential role of
hepatic-renal microRNA signalling we demonstrated that ECVs from
mice with liver injury prevented cisplatin toxicity in primary cells,
which is reported to be dependent on CYP2E1 activity. John et al.
reported that patients with acute liver failure who die have lower cir-
culating miR-122, which is consistent with miR-122 inter-organ
transfer having a possible protective effect in humans [27].
In summary, there is physiological transfer of microRNA from
the liver to the kidneys that is increased by hepatotoxicity and
regulates kidney CYP enzymes. miR-122 represents the majority
of the hepatocyte microRNA cargo and, following hepatotoxicity
in humans, it is the highest concentration microRNA in the circu-
lation. We propose miR-122 release (and potentially other micro-
RNA species) has the potential to mediate resistance to drug
toxicity in the kidney and may be, therefore, acting as a break on
multi-organ failure in the context of liver injury. With further
research and development, miR-122 may represent a treatment
to protect renal function in patients. Although there is a large
endogenous release of miR-122 into the circulation with liver
injury, it has a short half-life compared to ALT. We speculate that
continued treatment with miR-122 in patients with significant
liver injury could offer renal protection.5. Contributions
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